DISCLAIMER: THIS IS NOT INVESTMENT ADVICE. I AM NOT A FINANCIAL ADVISOR. THIS IS FOR EDUCATIONAL PURPOSES ONLY. DO NOT USE THIS INFORMATION FOR INVESTMENTS --MAX HITEK

Be sure to visit Piotr Pietrzkiewicz's Patreon blog "Bio- Scoping", patreon.com, for many interesting articles related to drug development! ---Max

A Comparison of Annovis and Anavex's Parkinson Disease Data

2024 07/26 ---Max Hitek

Definitions and Abbreviations

A2-73 - - Anavex's drug, also known as Blarcamesine.
Blarcamesine - - also known as A2-73 (Anavex's drug).
Butanetap - - Annovis's drug.
PD - - Parkinson Disease
PDD - - Parkinson Disease Dementia
MDS-UPDRS - - Movement Disorder Society-Unified Parkinson’s Disease Rating Scale” is a standardised test for assessing the Parkinson’s severity.
Part 2 - - This is Part two of the UPDRS test. It focuses on motor experiences of daily living/Activities.
Part 3 - - This is Part three of the UPDRS test. It focuses on motor examination and is the largest part of UPDRS.
EOT - - End Of Trial.
PIGD - - Postural Instability and Gait Difficulty (PIGD).

Annovis and Anavex are two clinical stage biotech companies attempting to address neurodegenerative diseases such as Parkinson's Disease (PD), and Alzheimer's Disease as well as other neuro diseases. They both recently published results from their PD trials. The results will be compared here.

Annovis's trial had about 523 PD patients in a 26 week trial. The trial was placebo controlled, with a high and mid dose. It was a P3 (late stage) trial and data can be found at clinicaltrials.gov with ID NCT05357989.

Anavex's trial had about 132 PDD patients, was placebo controlled, and was a 14 week trial. This trial also had a high and mid dose. It was a P2 (mid stage) trial and data can be found at clinicaltrials.gov with ID NCT03774459. The focus was on PD patients with probable dementia.

Both companies used UPDRS to evaluate the patient's Parkinson's disease, as it is the "gold standard" for Parkinson's testing. Both companies published unambiguous results, making comparisons straightforward. They both had data for UPDRS part 2 and part 3, as well as for the whole test. Both showed greatest efficacy with the high dose, so only high dose, and placebo, data will be analyzed. There is one difference in the two trials, which will be taken into account here. The Annovis trial was 26 weeks, while the Anavex trial was 14 weeks long. We will assume the Annovis response is linear and normalize the Annovis data to 14 weeks.

The table above shows the average scores, for the patients on the two drugs, for the UPDRS test Parts 2, 3, and ALL the parts. The scores are based on the HIGH dose score minus the placebo score, to offset the placebo effect. The Annovis numbers, that are in parentheses, are the 26 week scores (not normalized to 14 weeks). The higher the score the better. The A2-73 patients have scores that average 3.7 times better than the patients on Butanetap.

It should be noted that both companies had additional data. Only the common results are being analyzed here. For the other data see the references below. For example, Anavex patients had significant improvements in memory. Additionally, Annovis appears to have a subpopulation, with postural and walking issues (PIGD) which showed surprising improvement.

Below are the figures Annovis¹ published in their PR.

Below are the figures Anavex² published on their Parkinson's poster from 2022.

There was a great deal of collaboration with Piotr Pietrzkiewicz for this article. He has additional analysis, related to this article, as well as other pharma related articles. Visit his patreon blog at Bio-Scoping .

References:

¹ANNOVIS BIO ANNOUNCES NEW DATA FROM PHASE III PARKINSON’S STUDY For more information at www.annovisbio.com .

²Anavex website. For more information from Anavex, visit their website.